Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, discusses competition in the pharma sector and upcoming clinical trials. "One of the things that's particularly exciting for a lot of people is our approach to lowering cholesterol," says Schleifer.
CNBC's Seema Mody discusses the details of the deal between pharma companies Bristol-Myers and Amylin.
CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.
CNBC's David Faber reports the Dish Network and AMC contract expired without a new agreement, and a look at the deal between Bristol-Myers and Amylin Pharma.
CNBC's David Faber speaks to activist investor Carl Icahn regarding how much cash he has available to invest and whether Chesapeake Energy is undervalued.
Carl Icahn, Icahn Enterprises chairman, discusses his tender offer for CVR Energy, and now holds 69% of the company's shares. Icahn also weighs in on whether Amylin Pharma should be sold, and reveals his thoughts on RIMM, with the Fast Money traders.
Daniel Bradbury, Amylin CEO, explains the company's pricing strategy in Europe and how it will catch up with rival Novo Nordisk.
Dan Bradbury, Amylin CEO, discusses paying Lilly $250M upfront and $1.2B of future sales for the rights to Exenatide, the once weekly version of diabetes drug, Byetta, that's pending FDA approval.
Daniel Bradbury, Amylin president & CEO, discusses the company's new diabetes drug in Europe. Will it get approval in the US?